those with an AVF had a 32.8% lower risk of mortality compared with HC (aHR, 0.68; 95% CI, 0.67-0.69) wheras those with an AVG had a 19.8% lower risk of mortality compared with HC (aHR, 0.80; 95% CI, Fig). Sensitivity analysis matched by propensity to be wait listed confirmed inferences.
IP157. Objective: Previous studies have demonstrated lower morbidity and mortality after arteriovenous fistula (AVF) creation compared with arteriovenous grafts (AVGs) and hemodialysis (HD) catheters (HCs). The Fistula First Catheter Last coalition recommends AVF creation and usage rates of 50% and 68%, respectively, and limiting catheter use to <10%. Despite these recommendations, previous studies using the U.S. Renal Data System reported an incidence rate of AVF of 15%. The purpose of this study was to provide an update on trends in HD access creation and mortality in end-stage renal disease (ESRD) patients using the largest national renal database. Results: A total of 1,012,971 ESRD patients were identified, of which the majority initiated HD with HC (81%), followed by AVF (16%) and AVG (3%). During the study period (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , the incidence of HD using AVF increased slightly from 13.5% to 17.0%, whereas there was a decline in AVG (4.25% to 2.98%) and HC (82.25% to 80.01%; P < .001; Fig) . An overall decrease in 1-year mortality from 24.64% in 2006 to 18.54% in 2015 was also observed (P < .001; Fig) . Survival was higher in AVF vs AVG vs HC at 1 year (91.3% vs 86.8% vs 78.4%), 5 years (47.0% vs 40.2% vs 36.3%), and 10 years (12.6% vs 11.3% vs 12.3%), respectively (all P < .001). After adjustment for patients' demographics and comorbidities, AVF and AVG were associated with 29% (hazard ratio, 0.71; 95% confidence interval, 0.70-0.71; P < .001) and 13% (HR, 0.83; 95% confidence interval, 0.81-0.84; P < .001) lower mortality at 10 years compared with HC (Table) . Male sex, nonwhite race, obesity, hypertension, and nephrologist care were associated with lower mortality.
Conclusions: Using the entire U.S. HD database, we observed a modest increase of only 3.5% in the incidence of AVF during a decade. However, compared with HC, AVF was associated with a 29% survival benefit at 10 years. Despite the current Fistula First Catheter Last goal of 50% of incident AVF access, most patients continue to initiate HD with a catheter. It is clear that this goal is difficult to attain at this rate. Further study should be dedicated to understanding the barriers to AVF creation, and major changes in the policies and clinical practices are needed. 
IP159.

Inpatient Hemodialysis Access Surgery Results in Higher 30-Day and 2-Year Mortality Compared with Outpatient Surgery
Objective: Hemodialysis (HD) access surgery can be performed in either an inpatient or outpatient setting. Surgery in the inpatient setting may be preferable in that it avoids patients' being lost to follow-up and facilitates access maturation. However, inpatients have higher rates of comorbidities and acute medical conditions compared with outpatients, thus representing a theoretical higher risk surgical population. We hypothesize that those who receive HD access surgery as inpatients have higher rates of postoperative mortality compared with outpatients. 
